These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 21716130

  • 41. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
    Wittbrodt ET, Baum C, Peura DA.
    Clin Exp Gastroenterol; 2009; 2():117-28. PubMed ID: 21694835
    [Abstract] [Full Text] [Related]

  • 42. Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.
    Tammara BK, Sullivan JE, Adcock KG, Kierkus J, Giblin J, Rath N, Meng X, Maguire MK, Comer GM, Ward RM.
    Clin Pharmacokinet; 2011 Aug; 50(8):541-50. PubMed ID: 21740077
    [Abstract] [Full Text] [Related]

  • 43. Pharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease.
    Zannikos PN, Doose DR, Leitz GJ, Rusch S, Gonzalez MD, Solanki B, Haddad I, Mulberg AE.
    J Pediatr Gastroenterol Nutr; 2011 Jun; 52(6):691-701. PubMed ID: 21478756
    [Abstract] [Full Text] [Related]

  • 44. [How to choose correct proton pump inhibitors to patients with GERD?].
    Bordin DS.
    Eksp Klin Gastroenterol; 2010 Jun; (2):53-8. PubMed ID: 20496811
    [Abstract] [Full Text] [Related]

  • 45. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 46. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
    Springer M, Atkinson S, North J, Raanan M.
    Paediatr Drugs; 2008 Nov; 10(4):255-63. PubMed ID: 18590344
    [Abstract] [Full Text] [Related]

  • 47. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.
    Metz DC, Pilmer BL, Han C, Perez MC.
    Am J Gastroenterol; 2011 Nov; 106(11):1953-60. PubMed ID: 21844923
    [Abstract] [Full Text] [Related]

  • 48. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
    Lin XH, Luo JC, Ting PH, Chang TE, Huang YH, Hou MC, Lee FY.
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
    [Abstract] [Full Text] [Related]

  • 49. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.
    Andersson T, Hassall E, Lundborg P, Shepherd R, Radke M, Marcon M, Dalväg A, Martin S, Behrens R, Koletzko S, Becker M, Drouin E, Göthberg G.
    Am J Gastroenterol; 2000 Nov; 95(11):3101-6. PubMed ID: 11095324
    [Abstract] [Full Text] [Related]

  • 50. The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children.
    Lee JH, Kim MJ, Lee JS, Choe YH.
    Arch Dis Child; 2011 Jan; 96(1):9-13. PubMed ID: 20870626
    [Abstract] [Full Text] [Related]

  • 51. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
    Boccia G, Manguso F, Miele E, Buonavolontà R, Staiano A.
    Am J Gastroenterol; 2007 Jun; 102(6):1291-7. PubMed ID: 17319927
    [Abstract] [Full Text] [Related]

  • 52. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK, Cheng G, Tang J, Song J, Peng WX.
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [Abstract] [Full Text] [Related]

  • 53. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K.
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [Abstract] [Full Text] [Related]

  • 54. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
    Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK, Taiwan Acid-Related Disease Study Group.
    World J Gastroenterol; 2017 Dec 21; 23(47):8395-8404. PubMed ID: 29307999
    [Abstract] [Full Text] [Related]

  • 55. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.
    Clin Ther; 2007 Aug 21; 29(8):1692-705. PubMed ID: 17919550
    [Abstract] [Full Text] [Related]

  • 56. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.
    Kukulka M, Nudurupati S, Perez MC.
    Therap Adv Gastroenterol; 2016 Nov 21; 9(6):770-780. PubMed ID: 27803732
    [Abstract] [Full Text] [Related]

  • 57. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
    Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK, Taiwan Acid-Related Disease Study Group.
    Drug Des Devel Ther; 2019 Nov 21; 13():1347-1356. PubMed ID: 31118571
    [Abstract] [Full Text] [Related]

  • 58. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.
    Mermelstein J, Mermelstein AC, Chait MM.
    Clin Exp Gastroenterol; 2016 Nov 21; 9():163-72. PubMed ID: 27471402
    [Abstract] [Full Text] [Related]

  • 59. Heartburn severity does not predict disease severity in patients with erosive esophagitis.
    Fennerty MB, Johnson DA.
    MedGenMed; 2006 Apr 06; 8(2):6. PubMed ID: 16926745
    [Abstract] [Full Text] [Related]

  • 60. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D, Speed J, Medve R, Andrews JS.
    Clin Ther; 2010 Jan 06; 32(1):146-60. PubMed ID: 20171420
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.